Narlumosbart with SBRT shows promise in NSCLC with bone metastases in new Phase II trial
A Phase II trial is investigating narlumosbart, RANKL-targeting mAb, combined with SBRT and first-line chemotherapy/immunotherapy in NSCLC patients with bone metastases.
Phase II
Oncology / NSCLC
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing Phase II trial of narlumosbart combined with SBRT represents a potential shift in treatment paradigms for NSCLC patients with bone metastases. Positive outcomes could enhance therapeutic options and reshape competitive dynamics in the oncology market.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include patient enrollment progress and the primary endpoint results regarding objective response rates.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.